SYRE – spyre therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Spyre Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Leerink Partners to a "strong-buy" rating.
Spyre Therapeutics (NASDAQ:SYRE) had its price target raised by analysts at Wells Fargo & Company from $40.00 to $50.00. They now have an "overweight" rating on the stock.
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
Form EFFECT Spyre Therapeutics, Inc.
Form POS AM Spyre Therapeutics, Inc.
Form S-3 Spyre Therapeutics, Inc.
Form S-8 Spyre Therapeutics, Inc.
Form 8-K Spyre Therapeutics, Inc. For: Feb 19
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.